Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing central nervous system (CNS) therapies. Founded in 2005 and headquartered in Durham, North Carolina, the company specializes in treatments for conditions such as epilepsy, migraine, and psychiatric disorders. Supernus is known for its focus on formulations that improve patient adherence and quality of life.
Company News
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.
Investors need to pay close attention to Supernus (SUPN) stock based on the movements in the options market lately.
Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.